NAGE vs. CNTA, NAMS, RARE, SRRK, VKTX, XENE, MOR, IMVT, HCM, and KNSA
Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Centessa Pharmaceuticals (CNTA), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Immunovant (IMVT), HUTCHMED (HCM), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.
Niagen Bioscience vs. Its Competitors
Niagen Bioscience (NASDAQ:NAGE) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.
Niagen Bioscience presently has a consensus price target of $13.42, suggesting a potential upside of 38.64%. Centessa Pharmaceuticals has a consensus price target of $32.44, suggesting a potential upside of 47.34%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Niagen Bioscience.
Niagen Bioscience has a net margin of 15.24% compared to Centessa Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Centessa Pharmaceuticals' return on equity.
15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by company insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Niagen Bioscience has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Centessa Pharmaceuticals had 13 more articles in the media than Niagen Bioscience. MarketBeat recorded 16 mentions for Centessa Pharmaceuticals and 3 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.22 beat Centessa Pharmaceuticals' score of 0.15 indicating that Niagen Bioscience is being referred to more favorably in the media.
Niagen Bioscience has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
Summary
Niagen Bioscience beats Centessa Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Niagen Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Niagen Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:NAGE) was last updated on 9/16/2025 by MarketBeat.com Staff
Free NAGE Stock Alerts